Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Kentaro Ohara, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranai, Yasuharu Akasaki, et al. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathology. 2024. 41. 2. 61-72
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, et al. 10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT. Neuro-Oncology Advances. 2023. 5. Supplement_5. v1-v1
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Yohei Yamamoto, Ryotaro Imai, Yuki Kuranai, Kyoichi Tohmoto, Yuzuru Hasegawa, et al. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. 2023
Jun Takei, Yuko Kamata, Toshihide Tanaka, Nei Fukasawa, Kazutaka Gomisawa, Mari Satake, Ryosuke Mori, Yohei Yamamoto, Tomoya Suzuki, Ayaka Oda, et al. Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII. 2023
Tomoya Suzuki, Jun Takei, Nei Fukasawa, Kenta Suzuki, Daisuke Ogawa, Yohei Yamamoto, Yasuharu Akasaki, Yuichi Murayama, Masayuki Shimoda, Keisuke Miyake, et al. FMISO-PET and immunohistochemistry verified tumor oxygenation, stemness, and immunosupportive microenvironment after preoperative neoadjuvant bevacizumab for newly diagnosed glioblastoma. World neurosurgery. 2023. 175. e1364-e1374
MET-2 Clinical features of renal cell carcinoma brain metastases compared with other carcinomas. 2023. 5. 5. v4-v4
Akasaki Y, Kikuchi T, Tanaka T, Murayama Y. Dendritic cell immunotherapy for malignant glioma: Research history for 25 years and the future perspectives. Neuro-Oncology Advances. 2022. 4. 3. iii27
Akasaki Y, Suzuki T, Takei J, Tanaka T, Mori R, Koseki H, Yamamoto Y, Teshigawara A, Kamata Y, Yanagisawa T, et al. Pros and cons of surgical intervention for diffuse midline glioma aimed at dendritic cell immunotherapy. Neuro-Oncology Advances. 2022. 4. 3. iii12
Yamamoto Y, Nawate S, Nakamura A, Ishii T, Tanaka T, Akasaki Y, Murayama Y. Analysis of metastatic brain tumors discovered at the same time as the primary lesion. Neuro-Oncology Advances. 2022. 4. 3. iii21-iii22
Tohmoto K, Yamamoto Y, Tanaka T, Suzuki T, Teshigawara A, Takei J, Koseki H, Mori R, Akasaki Y, Murayama Y. Clinical benefit of add-on bevacizumab for newly diagnosed glioblastoma in elderly patients with unresectable and poor performance status. Neuro-Oncology Advances. 2022. 4. 3. iii8
